A myotonic dystrophy genetic test measures unstable DNA repeat expansions that cause myotonic dystrophy type 1 or type 2. Type 1, or DM1, results from a CTG repeat expansion in DMPK. Type 2, or DM2, results from a CCTG expansion in CNBP. These are targeted repeat tests, not ordinary gene sequencing. The correct assay can confirm a diagnosis with a blood sample, distinguish DM1 from DM2, guide heart and breathing surveillance, and identify relatives who may be at risk. Repeat size provides useful context, especially in DM1, but it does not predict one person’s exact age of onset, symptoms, or rate of progression. Large expansions can also be difficult to size precisely because repeat length varies among tissues and even among blood cells. A negative exome or standard neuromuscular panel does not exclude myotonic dystrophy unless the laboratory specifically validated repeat-expansion detection. Testing should be paired with genetic counseling because results affect multiple organ systems, relatives, pregnancy planning, and anesthesia care.
- DM1 is caused by a DMPK CTG expansion; DM2 is caused by a CNBP CCTG expansion.
- Repeat-primed PCR and other specialized methods are needed to detect large expansions.
- DM1 can range from mild adult disease to congenital myotonic dystrophy.
- DM2 usually causes adult-onset proximal weakness, stiffness, myotonia, and muscle pain.
- Repeat size cannot serve as an exact personal prognosis.
- A confirmed result should trigger cardiac, respiratory, endocrine, eye, and anesthesia planning.
Table of Contents
- Why myotonic dystrophy is a multisystem condition
- DM1 and DM2 compared
- How repeat-expansion testing works
- DMPK result ranges in DM1
- Understanding CNBP results in DM2
- Inheritance, anticipation, and pregnancy
- Limitations, negative results, and mimics
- Medical care after diagnosis
Why myotonic dystrophy is a multisystem condition
Myotonia is delayed relaxation after a muscle contracts. A person may have trouble releasing a handshake, opening the hand after gripping an object, or relaxing the jaw after biting. Cold can worsen stiffness. Myotonic dystrophy also causes progressive muscle weakness and wasting, but the disease extends well beyond skeletal muscle.
DM1 often affects facial muscles, neck flexors, forearms, hands, and ankle dorsiflexors. Early clues can include drooping eyelids, a long facial appearance, weak grip, foot drop, daytime sleepiness, cataracts at a young age, or difficulty with speech and swallowing. Some people have only mild symptoms, while congenital DM1 can present before birth or at delivery with reduced fetal movement, excess amniotic fluid, severe newborn hypotonia, breathing failure, feeding difficulty, and later developmental or learning challenges.
DM2 more often begins with hip, thigh, neck, or other proximal weakness, muscle pain, stiffness, and fatigue. Myotonia may be mild or difficult to detect on examination. Facial and distal weakness are generally less prominent than in DM1. DM2 has not traditionally been associated with the typical severe congenital form seen in DM1, although rare early presentations have been reported.
Both types can affect cardiac conduction and rhythm. A person may have no warning symptoms before an electrocardiogram shows disease. Cardiomyopathy can occur. Respiratory muscle weakness, ineffective cough, aspiration, and sleep-disordered breathing are important causes of illness. Excessive daytime sleepiness can reflect central nervous system effects, nocturnal hypoventilation, sleep apnea, medication, or several factors together.
Other manifestations include cataracts, insulin resistance or diabetes, thyroid and other endocrine abnormalities, gastrointestinal motility problems, constipation or diarrhea, gallbladder disease, reproductive problems, and increased anesthesia sensitivity. DM1 can affect attention, executive function, behavior, and social cognition, with wide individual variation. Both types are associated with higher risk for selected tumors, but screening generally follows standard population guidance plus condition-specific clinical recommendations rather than an unproven universal cancer panel.
Because the condition is multisystemic, the diagnosis may first arise in cardiology, ophthalmology, sleep medicine, endocrinology, fertility care, pediatrics, or anesthesia rather than neurology. A family history of “muscle weakness” may miss relatives whose main features were cataracts, pacemaker placement, sudden death, infertility, or unexplained newborn complications.
DM1 and DM2 compared
DM1 and DM2 share a toxic RNA mechanism. The expanded repeat is copied into RNA, which accumulates and traps proteins that regulate RNA splicing. Many other genes are then processed incorrectly, producing effects in muscle, heart, brain, endocrine tissue, and other organs. The expansion does not mainly cause disease by eliminating DMPK or CNBP protein.
| Feature | DM1 | DM2 |
|---|---|---|
| Gene and repeat | DMPK CTG repeat | CNBP CCTG repeat within a complex repeat tract |
| Typical weakness | Facial, neck, distal limb, and later proximal muscles | Proximal and axial muscles, often hips and neck |
| Muscle pain | Can occur | Often prominent and sometimes fluctuating |
| Congenital form | Well established, usually after maternal transmission | No usual classic congenital form |
| Repeat-size relationship | Broad correlation with onset and severity, but large overlap | Repeat size is generally not useful for predicting severity |
| Inheritance | Autosomal dominant with frequent anticipation | Autosomal dominant; intergenerational behavior is more complex |
The two disorders cannot be separated reliably by one symptom. Proximal weakness can occur in DM1, distal weakness can occur in DM2, and myotonia can be subtle in either. Electromyography may show myotonic discharges but cannot identify the gene. CK is often normal or mildly elevated and is not diagnostic.
When the presentation is classic for DM1, DMPK testing can be ordered first. When proximal pain and weakness predominate or DMPK testing is negative despite a myotonic phenotype, CNBP analysis is important. Some laboratories offer both together. A combined order can reduce delay when clinical distinction is uncertain.
Other disorders also cause myotonia. CLCN1 and SCN4A channelopathies usually do not produce the same cataract, cardiac, endocrine, or cognitive pattern. Pompe disease, inflammatory myopathy, limb-girdle muscular dystrophy, mitochondrial disease, motor neuron disease, and medication effects can resemble parts of DM1 or DM2. The examination and family history help determine whether repeat testing alone is enough.
A confirmed molecular result is usually definitive because nearly all classic DM1 and DM2 are caused by their respective repeat expansions. Rare people can have two diagnoses, so a result should not be forced to explain an unrelated feature that falls outside the expected spectrum.
How repeat-expansion testing works
Standard PCR and fragment analysis can size alleles within an amplifiable range. A very large expanded repeat may fail to amplify, creating an apparent result with only one normal allele. Repeat-primed PCR is designed to reveal the presence of an expansion even when the full length cannot be copied. Southern blot or newer long-range methods may estimate the size of a large DM1 expansion. DM2 testing uses specialized repeat-primed approaches because pathogenic CNBP expansions are often thousands of repeats long.
The laboratory should report both detection and sizing limitations. For DM1, small and moderate expansions can often be sized with reasonable precision. Very large expansions may be reported as greater than a threshold or as an approximate range. Exact sizing is less important than correctly identifying a pathogenic expansion, especially because repeat length is biologically variable.
Somatic mosaicism means the expansion differs among cells in one person. DMPK repeats often grow in some tissues over time, so blood may contain a distribution of repeat sizes rather than one perfectly fixed number. Muscle and other tissues may have larger expansions than blood. Two blood samples taken years apart can produce different estimates without changing the inherited diagnosis.
The repeat can also contain interruptions. Interrupted DMPK expansions may be more stable and can modify the relationship between repeat length and phenotype. Some routine assays do not characterize internal sequence. Additional analysis may be considered when the repeat behaves unexpectedly in a family or when precise reproductive counseling requires it, but interruption testing is not necessary to diagnose most DM1.
Exome sequencing generally does not detect DMPK or CNBP expansions because the causal repeats are noncoding and technically difficult. Short-read genome sequencing can identify some repeat expansions when the pipeline is specifically validated, but a “negative genome” is only meaningful if the report states that DMPK and CNBP repeat analysis was performed. A neurologic genetic panel with the gene names listed may still provide ordinary sequencing rather than expansion testing.
Samples should be analyzed in a clinical laboratory experienced with repeat disorders. A consumer genotype, rare SNP near DMPK, or research estimate is not a substitute. When a family variant is known, relatives still need repeat testing; the expansion is not usually represented by a simple single-letter variant that can be checked on a standard array.
Prenatal and preimplantation testing require advance laboratory planning. Large expansions, mosaicism, parental samples, and the need to avoid sample mix-up or maternal-cell contamination make quality procedures essential.
DMPK result ranges in DM1
DM1 reports classify the larger DMPK CTG repeat. Laboratories may use slightly different wording, but current clinical interpretation commonly follows these ranges:
| CTG repeats | Usual classification | Typical interpretation |
|---|---|---|
| 5–34 | Normal | Stable and not expected to cause DM1 |
| 35–49 | Premutation or mutable normal | Usually not associated with DM1 symptoms, but may expand in descendants |
| 50 or more | Full-penetrance expansion | Confirms DM1; phenotype ranges from mild to congenital disease |
A result of 50 or more repeats establishes DM1 in an appropriate clinical context. “Full penetrance” means a disease-associated expansion, but manifestation can be very mild and age dependent at the lower end. Some people with small expansions are diagnosed only after cataract surgery, mild myotonia, or family testing.
Broad phenotype categories are often described. Mild DM1 commonly involves roughly 50 to 100 repeats; classic adult DM1 often involves about 100 to 1,000; and congenital DM1 frequently has very large expansions, often above 1,000. These ranges overlap substantially and should not be treated as rigid boundaries. The measured blood size, age-related somatic change, interruptions, and other modifiers limit prediction.
A person with 400 repeats cannot be told exactly when walking, cardiac, breathing, or cognitive problems will occur. Family members with similar reported sizes can differ. Repeat length has a stronger group-level relationship to onset and severity than many ordinary variants, yet it remains an unreliable personal timetable.
Premutation alleles between 35 and 49 repeats usually do not cause clinical DM1 in the carrier. They can be unstable when passed to children and may expand into a pathogenic range in later generations. Counseling depends on repeat size, parent of origin, and family pattern. The report should not call such a person affected solely because the repeat exceeds the normal range.
A normal DMPK result makes DM1 very unlikely if the assay can detect large expansions and did not mistake apparent homozygosity for a hidden allele. It does not exclude DM2 or a non-dystrophic myotonia. When the phenotype strongly suggests myotonic dystrophy, the clinician should confirm that repeat-primed analysis was included and consider CNBP testing.
Newborn or childhood findings require careful correlation. A very large maternal expansion supports congenital DM1, but management is based on the infant’s respiratory, feeding, cardiac, developmental, and motor needs rather than the number alone.
Understanding CNBP results in DM2
DM2 is caused by a heterozygous pathogenic expansion of a CCTG repeat within a complex CNBP repeat structure. Pathogenic expansions generally range from about 75 to more than 11,000 CCTG repeats, with many measuring in the thousands. The size is often reported qualitatively or approximately because the repeat is extremely long, mosaic, and structurally complex.
Normal alleles are much shorter. Laboratories may describe an intermediate or uncertain interval between clearly normal and clearly pathogenic alleles, and their exact cutoffs and measurement tolerances can differ. The report should be interpreted using that laboratory’s validated method rather than transferring a number from a different assay.
A detected large pathogenic expansion confirms DM2. Repeat length does not correlate consistently enough with onset or severity to serve as a prognosis. A person with a larger measured expansion is not necessarily more affected than a relative with a smaller one. The structure and uninterrupted CCTG portion may matter biologically, but routine reports do not yet translate this into precise clinical predictions.
DM2 testing can produce false negatives if the repeat-primed assay is poorly designed or if unusual repeat structures interfere with primer binding. Updated research has shown that CNBP expansions are more structurally varied than older simplified models suggested. An expert laboratory may use bidirectional repeat-primed PCR, long-range PCR, Southern blot, optical genome mapping, or another confirmatory method when the first assay is inconclusive.
Apparent homozygosity for one short allele should be handled carefully because a large expansion may not amplify with ordinary PCR. The laboratory needs an expansion-detection method rather than assuming both gene copies have the same normal size. This principle is similar to other repeat-expansion disorders.
A negative CNBP result reduces the likelihood of DM2 only when the assay had adequate sensitivity for large expansions. If clinical myotonia, proximal weakness, pain, cataracts, and family history remain compelling, the clinician can request technical review or testing at another experienced laboratory before abandoning the diagnosis.
A VUS framework used for ordinary sequence changes is not usually the main issue in DM2; the core result is whether a pathogenic expansion is present. However, small or atypical repeat structures can be uncertain, and they should not be treated as a confirmed diagnosis without laboratory and clinical support.
Inheritance, anticipation, and pregnancy
DM1 and DM2 are autosomal dominant. Each child of an affected person has a 50% chance of inheriting the expanded allele. That transmission probability is separate from severity. A child who inherits a DM1 expansion may have milder, similar, or more severe disease than the parent, although expansion and earlier onset are common across generations.
Anticipation is especially important in DM1. The CTG repeat tends to enlarge when transmitted, leading to earlier onset or more severe disease in later generations. Large expansions can occur through either parent, but congenital DM1 is overwhelmingly associated with transmission from an affected mother. A woman may have mild, unrecognized DM1 while her newborn is severely affected.
Pregnancy in a woman with DM1 can involve polyhydramnios, reduced fetal movement, preterm delivery, prolonged labor, anesthesia complications, respiratory issues, and postpartum risks. A fetus with congenital DM1 may have clubfeet or other signs of reduced movement. Obstetric, anesthesia, cardiology, respiratory, neonatal, and genetics teams should plan together.
Paternal transmission of a DMPK expansion can also produce affected children and anticipation. The relationship between parent sex and repeat change is not absolute, especially for smaller expansions. Counseling should use the actual family data rather than a statement that only mothers transmit severe disease.
DM2 also shows unstable transmission, but classic anticipation and congenital disease are less predictable and less clearly tied to repeat size. Recent studies have explored parent-of-origin effects, yet routine counseling still cannot forecast a child’s age of onset from the parental expansion length.
Predictive testing is available to adults at 50% risk. Because a positive result can uncover future cardiac and other medically actionable risks, testing may have direct health value. It should still be voluntary and include discussion of emotional effects, family communication, privacy, and insurance rules. Testing a child is appropriate when symptoms are present or when the result will change childhood medical surveillance; purely predictive testing requires individualized ethics review.
Reproductive choices include natural conception with or without prenatal testing, in vitro fertilization with preimplantation genetic testing, donor gametes, adoption, or not pursuing pregnancy. Repeat-expansion testing for embryos or fetuses requires a laboratory with relevant experience. Exact repeat size may be difficult to predict from a prenatal sample and should not be presented as a certain severity forecast.
Testing relatives should begin with the actual report from the diagnosed family member. A family letter can state whether DMPK or CNBP is involved, because “myotonic dystrophy” without the type is not enough for correct targeted testing.
Limitations, negative results, and mimics
A negative test can be misleading when the wrong method was used. Ordinary DMPK or CNBP sequencing looks for small spelling changes but does not necessarily detect the repeat expansion. The order and report must explicitly state CTG or CCTG repeat-expansion analysis. Exome sequencing, microarray, and most routine carrier screens cannot be assumed to cover these disorders.
A technically complete negative result for both expansions should prompt reassessment. Myotonia with minimal systemic disease can result from CLCN1-related myotonia congenita or SCN4A-related sodium-channel myotonia. Periodic paralysis, paramyotonia, and hyperkalemic episodes have different triggers and gene associations. Electromyography, potassium history, exercise response, and targeted panel testing can help.
Proximal weakness and high CK may suggest a limb-girdle muscular dystrophy, inflammatory myopathy, Pompe disease, thyroid disease, medication toxicity, or another metabolic myopathy. Facial weakness, cardiomyopathy, neuropathy, motor neuron disease, and mitochondrial conditions can also overlap. A limb-girdle muscular dystrophy genetic test evaluates different mechanisms and should not be substituted for repeat analysis when myotonia and multisystem features point to DM.
Large-repeat sizing varies across laboratories and samples. A report showing 700 repeats and a later report showing 900 does not necessarily indicate rapid clinical worsening; both may be estimates of a mosaic distribution. Repeating the test for disease monitoring is generally not useful. Clinical measurements of strength, heart rhythm, breathing, swallowing, sleep, and function are more important.
Prenatal repeat size has limited prognostic precision. Very large DMPK expansions raise concern for congenital DM1, but overlap and technical uncertainty remain. Families need balanced counseling about what the test can establish and what ultrasound, fetal movement, family history, and neonatal preparation add.
A small repeat near a boundary may require confirmation and parental studies. Sample identity, maternal-cell contamination in prenatal specimens, and allele dropout are quality concerns. Laboratories should follow current technical standards and explain uncertainty rather than forcing a definitive category.
A negative family test is informative only if it targeted the correct expansion. If an affected relative was diagnosed clinically without molecular confirmation, testing them first is preferable. Phenocopies and mistaken family labels can otherwise create false reassurance.
Medical care after diagnosis
A confirmed diagnosis should lead to multidisciplinary care, not only a neurology follow-up. Baseline cardiac evaluation usually includes an electrocardiogram and often cardiac imaging, with rhythm monitoring or electrophysiology referral based on age, type, symptoms, and findings. Fainting, palpitations, chest pain, or unexplained breathlessness requires prompt assessment because conduction disease can be serious before muscle weakness appears advanced.
Respiratory evaluation may include seated and supine lung function, cough strength, sleep study, and carbon dioxide assessment. Morning headaches, excessive sleepiness, weak cough, recurrent infections, or difficulty breathing when lying flat can indicate nocturnal hypoventilation or sleep apnea. Noninvasive ventilation and cough assistance can be lifesaving when indicated.
Anesthesia deserves special planning. People with DM are not defined by classic malignant hyperthermia susceptibility, but they can have severe sensitivity to sedatives, opioids, neuromuscular blockers, aspiration, respiratory depression, arrhythmia, and prolonged recovery. Succinylcholine can provoke problematic muscle contraction and is generally avoided. The anesthesia team should receive the diagnosis and current cardiac and respiratory assessments before any procedure, including endoscopy and dental sedation.
Regular eye examinations identify cataracts. Endocrine and metabolic monitoring may include glucose, thyroid function, and other tests based on symptoms. Swallowing, nutrition, bowel function, pain, fatigue, and sleep should be addressed directly. Pregnancy and reproductive care require condition-specific coordination.
Myotonia can sometimes be treated with medication, but cardiac status and drug interactions matter. Physical and occupational therapy can support safe activity, stretching, energy conservation, orthoses, and adaptive equipment. Exercise should be individualized; inactivity can worsen conditioning, while unsafe intensity may increase falls or fatigue.
Children with congenital or childhood DM1 may need respiratory, feeding, physical, speech-language, developmental, educational, behavioral, and cardiac support. Cognitive and adaptive needs can be as important as muscle weakness. Family members may themselves have undiagnosed DM1 and difficulty organizing complex care, so services should be accessible and concrete.
There is currently no routine treatment that removes the expansion, although RNA-targeted and other disease-modifying therapies are under study. Clinical trials use specific eligibility criteria and should not displace proven surveillance. A genetic result may enable research participation, but personal benefit is uncertain.
The person should keep a copy of the laboratory report, a current medication list, and an emergency or anesthesia card. Relatives should receive the exact type and gene, not only a verbal diagnosis. The purpose of testing is fulfilled when the repeat result becomes a practical plan for heart safety, breathing, daily function, pregnancy, procedures, and informed family choices.
References
- Myotonic Dystrophy Type 1 (2024, GeneReviews)
- Myotonic Dystrophy Type 2 (2025, GeneReviews)
- Myotonic Dystrophy Type 1 Testing, 2024 Revision: A Technical Standard of the American College of Medical Genetics and Genomics (2024)
- Updated Structure of CNBP Repeat Expansions in Patients With Myotonic Dystrophy Type 2 and Its Implication for Standard Diagnostics (2024)
- Myotonic Dystrophy Testing and Diagnosis (2025, Myotonic Dystrophy Foundation)
- International Collaboration to Improve Knowledge on Myotonic Dystrophy Type 2 (2024)
Disclaimer
This article is for general education and does not replace diagnosis, genetic counseling, or care from neuromuscular, cardiac, respiratory, obstetric, or anesthesia professionals. Repeat-size estimates cannot predict an individual course, and test methods vary by laboratory. Seek urgent medical care for fainting, severe breathing difficulty, chest pain, marked swallowing problems, or a newborn with respiratory or feeding failure.
